AKBA compared with FLGT: revenue, margins and what each company keeps, and the suppliers and customers both name

AKBAAkebia Therapeutics, Inc.

Mkt capRevenueRevenue

FLGTFulgent Genetics, Inc.

Mkt capRevenueRevenue

Compare

AKBAAkebia Therapeutics, Inc.

FLGTFulgent Genetics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AKBA 21

CAHCardinal Healthsupplier

DVADaVitacustomer

QTTBQ32 Biosupplier

CYCNCyclerion Therapeuticssupplier

17 more · AKBA chain ›

Shared 0

No shared counterparties.

Only FLGT 4

ABTAbbott Laboratoriessupplier

ILMNIlluminasupplier

—Leica Biosystemsunlistedsupplier

—Roche

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

unlistedsupplier

AKBAAkebia Therapeutics, Inc.

0.40▼−6.02%· post 0.40

Mkt cap$111.4MRevenue$37MQ3 FY26Revenue$236MFY25

FLGTFulgent Genetics, Inc.

23.79▲+27.52%· post 23.79

ClosedNov 6 '26

Mkt cap$663.3MRevenue$90MQ3 FY26Revenue$323MFY25

Compare

ClosedNov 6 '26

AKBAAkebia Therapeutics, Inc.

FLGTFulgent Genetics, Inc.

0.40▼−6.02%post 0.40

Price

23.79▲+27.52%post 23.79

$111.4M

Mkt cap

$663.3M

Q3 FY26$37M

Revenue

$90MQ3 FY26

FY25$236M

Revenue

$323MFY25

AKBA0.40▼−6.02%vsFLGT23.79▲+27.52%ClosedNov 6 '26